|I-45 Ana Novakovic|
Sample size calculations in multiple sclerosis using pharmacometrics methodology: comparison of a composite score continuous modeling and Item Response Theory approach
|II-11 Giulia Lestini|
Two-stage adaptive designs in nonlinear mixed-effects models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic (PD) model in oncology
|II-22 France Mentrť|
PFIM 4.0: new features for optimal design in nonlinear mixed effects models using R
|III-05 Claire Ambery|
Bayesian bio-comparability using small sample sizes and quantification of safety risk
|III-11 Charlotte Barker|
Synthesising pragmatic and optimal design: NAPPA - a paediatric penicillin population pharmacokinetic study
|III-22 Ari Brekkan Viggosson|
Optimized Reduced Designs of Pharmacokinetic Clinical Trials Utilizing Target Mediated Drug Disposition Models
|III-42 Oskar Clewe|
A bronchoalveolar lavage study design framework for characterization of the rate and extent of pulmonary distribution
|III-44 Teresa Collins|
Performance of composite and serial study designs for estimation of toxicokinetic parameters.
|III-55 Thomas Dorlo|
Sample size estimates for a clinical trial evaluating allometric dosing of miltefosine in children with visceral leishmaniasis in East Africa
|IV-20 Eric StrŲmberg|
Design evaluation using a bootstrapped Monte Carlo variance-covariance matrix.
|IV-47 Sebastian Wicha|
Adaptive optimal design for the concentration tiers in time-kill curve experiments.
|IV-50 Shuying Yang|
Probability of Success with Exposure Response Modelling and Clinical Trial Simulation as a Tool to Support Decision Making